Atherosclerotic Cardiovascular Disease: key endpoint results by drug
The key endpoints of Atherosclerotic Cardiovascular Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Atherosclerotic Cardiovascular Disease page.
LDL-C, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Alirocumab | -52.7% | -0.3% | −52.4 | 300 mg Q4W/Up 150 mg Q2W · wk 24 · n 144 | NCT01926782 Phase 3, primary |
| Bempedoic acid | -22.6% | -1.2% | −21.4 | wk 12 · n 224 | NCT02988115 Phase 3, primary |
| Bempedoic acid/ezetimibe | -36.2% | 1.8% | −38 | 180 mg + 10 mg FDC · wk 12 · n 86 | NCT03337308 Phase 3, primary |
| Berberine ursodeoxycholate (HTD1801) | -9.8% | -3.6% | −6.2 | 1000 mg BID · wk 4 · n 12 | NCT03381287 Phase 1/2, secondary |
| Colestilan | -27.5% | 2.8% | −30.2 | 15 g · wk 12 · n 99 | NCT00542386 Phase 3, primary |
| Enlicitide | -58.2% | 2.6% | −60.8 | wk 24 · n 198 | NCT05952869 Phase 3, primary |
| Evolocumab | -50.1% | 6.8% | −57 | wk 52 · n 599 | NCT01516879 Phase 3, primary |
| Ezetimibe | -27.7% | -0.9% | −26.7 | wk 12 · n 85 | NCT00867165 Phase 3, primary |
| Ezetimibe/simvastatin (Vytorin) | -49.3% | -38.0% (Atorvastatin) | — | 10/20 mg · wk 8 · n 124 | NCT00496730 Phase 3, primary |
| Hyzetimibe | -16.4%a | -6.8% (atorvastatin alone) | — | wk 12 | NCT03433196 Phase 3, primary |
| Icosapent Ethyl | 1.5% | 8.8% | −7.3 | 4 g/day · wk 12 · n 225 | NCT01047501 Phase 3, secondary |
| Inclisiran | -49.3% | 4.2% | −53.5 | wk 72.9 · n 810 | NCT03400800 Phase 3, primary |
| Laroprovstat | -46.6% | 4.1% | −50.7 | 30 mg · wk 12 · n 85 | NCT06173570 Phase 2, primary |
| Lerodalcibep | -9.3%a | -11% (evolocumab) | — | wk 24 | NCT04034485 Phase 3, primary |
| Obicetrapib | -29.9% | 2.7% | −32.6 | 10mg · wk 12 · n 1679 | NCT05142722 Phase 3, primary |
| Olpasiran | -16.7% | 6.2% | −23 | 225 mg Q12W · wk 36 · n 54 | NCT04270760 Phase 2, secondary |
| Pelacarsen | -16% | -1% | −15 | 60 mg Q4W · n 47 | NCT03070782 Phase 2, secondary |
| Pemafibrate | 31.5% | 2.3% | +29.2 | wk 12 · n 311 | NCT03011450 Phase 3, secondary |
| Recaticimab | -51%a | 2% | −53 | 450mg Q12W · wk 24 | NCT04885218 Phase 3, primary |
| Resmetirom | -10.6% | 8.2% | −18.8 | wk 12 · n 76 | NCT03038022 Phase 2, primary |
| Rosuvastatin | -38.5% | -0.5% | −38 | 5 mg · wk 12 · n 42 | NCT00355615 Phase 3, primary |
| Tafolecimab | -58.7%a | 3.2% | −61.9 | tafolecimab 450mg Q4W · wk 12 | NCT04179669 Phase 3, primary |
Drugs checked with no result here: 26 not reported, 21 trial running, 15 not posted.
Non-HDL-C, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Alirocumab | -53.7% | 0.9% | −54.6 | 150 mg Q2W · wk 12 · n 1530 | NCT01507831 Phase 3, secondary |
| Bempedoic acid | -11.9% | 1.5% | −13.4 | wk 12 · n 1488 | NCT02666664 Phase 3, secondary |
| Bempedoic acid/ezetimibe | -31.9% | 1.8% | −33.7 | 180 mg + 10 mg FDC · wk 12 · n 86 | NCT03337308 Phase 3, secondary |
| Enlicitide | -52.3% | 2.1% | −54.4 | wk 24 · n 198 | NCT05952869 Phase 3, secondary |
| Evolocumab | -41.8% | 8.4% | −50.3 | wk 52 · n 599 | NCT01516879 Phase 3, secondary |
| Ezetimibe | -55.6% | -51% | −4.6 | wk 12 · n 262 | NCT00639158 Phase 3, secondary |
| Icosapent Ethyl | -5% | 9.8% | −14.8 | 4 g/day · wk 12 · n 226 | NCT01047501 Phase 3, secondary |
| Inclisiran | -41.2% | 2.1% | −43.3 | wk 72.9 · n 810 | NCT03400800 Phase 3, secondary |
| Laroprovstat | -41.6% | 3.5% | −45.2 | 30 mg · wk 12 · n 85 | NCT06173570 Phase 2, secondary |
| Obicetrapib | -26.6% | 2.8% | −29.4 | 10mg · wk 12 · n 1685 | NCT05142722 Phase 3, secondary |
| Pemafibrate | -21.0% | -3.4% | −17.5 | wk 12 · n 311 | NCT03011450 Phase 3, secondary |
| Resmetirom | -12% | 7.5% | −19.5 | wk 12 · n 76 | NCT03038022 Phase 2, secondary |
| Rosuvastatin | -36.3% | -0.8% | −35.5 | 5 mg · wk 12 · n 42 | NCT00355615 Phase 3, secondary |
Drugs checked with no result here: 27 not reported, 22 trial running, 22 not posted.
ApoB, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Alirocumab | -55.5% | 0.5% | −56 | 150 mg Q2W · wk 12 · n 1468 | NCT01507831 Phase 3, secondary |
| Bempedoic acid | -8.6% | 3.3% | −11.9 | wk 12 · n 1485 | NCT02666664 Phase 3, secondary |
| Bempedoic acid/ezetimibe | -24.6% | 5.5% | −30.1 | 180 mg + 10 mg FDC · wk 12 · n 82 | NCT03337308 Phase 3, secondary |
| Enlicitide | -48.2% | 1.8% | −50 | wk 24 · n 197 | NCT05952869 Phase 3, secondary |
| Evolocumab | -41.3% | 2.9% | −44.2 | wk 52 · n 599 | NCT01516879 Phase 3, secondary |
| Ezetimibe | -49.1% | -44.7% | −4.4 | wk 12 · n 248 | NCT00639158 Phase 3, secondary |
| Icosapent Ethyl | -2.2% | 7.1% | −9.3 | 4 g/day · wk 12 · n 217 | NCT01047501 Phase 3, secondary |
| Inclisiran | -38.1% | 0.8% | −38.9 | wk 72.9 · n 810 | NCT03400800 Phase 3, secondary |
| Laroprovstat | -37.0% | 2.9% | −39.9 | 30 mg · wk 12 · n 85 | NCT06173570 Phase 2, secondary |
| Lepodisiran | -13.9% | 0.2% | −14.1 | 400 mg · wk 8.57 · n 69 | NCT05565742 Phase 2, secondary |
| Muvalaplin | -17.6% | -1.7% | −15.9 | 240 mg · wk 12 · n 57 | NCT05563246 Phase 2, secondary |
| Obicetrapib | -17.8% | 1.1% | −18.9 | 10mg · wk 12 · n 1685 | NCT05142722 Phase 3, secondary |
| Olpasiran | -10.2% | 7.4% | −17.6 | 225 mg Q12W · wk 36 · n 54 | NCT04270760 Phase 2, secondary |
| Pelacarsen | -8% | 1% | −9 | 60 mg Q4W · n 47 | NCT03070782 Phase 2, secondary |
| Pemafibrate | 0.6% | -1.7% | +2.2 | wk 12 · n 311 | NCT03011450 Phase 3, secondary |
| Resmetirom | -14.2% | 3.8% | −18 | wk 12 · n 76 | NCT03038022 Phase 2, secondary |
| Rosuvastatin | -32.1% | -1.5% | −30.6 | 5 mg · wk 12 · n 42 | NCT00355615 Phase 3, secondary |
Drugs checked with no result here: 27 not reported, 19 trial running, 21 not posted.
Lp(a), % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Alirocumab | -28.2% | -3.1% | −25.1 | 150 mg Q2W · wk 12 · n 1530 | NCT01507831 Phase 3, secondary |
| Bempedoic acid | 16.2% | -2.7% | +18.9 | 120 mg · wk 12 · n 38 | NCT01262638 Phase 2, secondary |
| Berberine ursodeoxycholate (HTD1801) | -21.9% | 10.6% | −32.5 | 1000 mg BID · wk 4 · n 12 | NCT03381287 Phase 1/2, secondary |
| Enlicitide | -24.7% | -1.6% | −23.1 | wk 24 · n 196 | NCT05952869 Phase 3, secondary |
| Evolocumab | -27.7% | -5.4% | −22.3 | wk 52 · n 599 | NCT01516879 Phase 3, secondary |
| Inclisiran | -4.6% | 4.3% | −8.9 | wk 12.86 · n 37 | NCT03851705 Phase 3, secondary |
| Laroprovstat | -19.4% | 0% | −19.4 | 30 mg · wk 12 · n 76 | NCT06173570 Phase 2, secondary |
| Lepodisiran | -74.4% | 3.1% | −77.5 | 96 mg · n 74 | NCT05565742 Phase 2, primary |
| Muvalaplin | -85.7% | 0.5% | −86.2 | 240 mg · wk 12 · n 47 | NCT05563246 Phase 2, primary |
| Obicetrapib | -0.5% | 13.7% | −14.1 | 10mg · wk 12 · n 1685 | NCT05142722 Phase 3, secondary |
| Olpasiran | -97.5% | 3.6% | −101.1 | 225 mg Q12W · wk 36 · n 53 | NCT04270760 Phase 2, primary |
| Pelacarsen | -72% | -6% | −66 | 60 mg Q4W · n 47 | NCT03070782 Phase 2, primary |
| Resmetirom | -21.8% | 4.4% | −26.2 | wk 12 · n 76 | NCT03038022 Phase 2, secondary |
| Rosuvastatin | -20.7% | 3.5% (Rosuvastatin) | — | 75 mg/up to 150 mg + 10 mg · wk 12 · n 48 | NCT01730053 Phase 3, secondary |
Drugs checked with no result here: 26 not reported, 20 trial running, 24 not posted.
3-point MACE (% with event)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Evolocumab | 7.9% | 9.9% | −2 | wk 156 · n 13784 | NCT01764633 Phase 3, secondary |
| Icosapent Ethyl | 11.2% | 14.8% | −3.6 | n 4089 | NCT01492361 Phase 3, secondary |
| Liraglutide (Victoza) | 13% | 14.9% | −1.9 | wk 260 · n 4668 | NCT01179048 Phase 3, primary |
Drugs checked with no result here: 27 not reported, 25 trial running, 29 not posted.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 84 approved or late-stage drugs with a featured trial in Atherosclerotic Cardiovascular Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.